Boehringer Ingelheim
For Healthcare Professionals
x

Registration Form

When do you usually screen for PPF (eg, PFTs, HRCT)?

When do you initiate antifibrotic treatment in PPF patients?

Information you provide when registering will be shared with the account owner and host and can be used and shared by them in accordance with their Terms and Privacy Policy.

This webinar is for Health Care Professionals only. Upon submitting this registration, I am confirming that I am a Health Care Professional.

home hero
icon patient
RA patients experience ILD within 5-10 years of disease progression1-7
icon second
ILD is 2nd leading cause of premature death in RA, after cardiovascular complications1-4,8

There are currently no recommendations on ILD screening in either the initial assessment or in the follow-up of RA patients.

The RA-EPIDSER expert consensus group consisting of 18 expert panelists including 9 pulmonologists and 9 rheumatologists proposed a RA-ILD risk scoring with selective screening criteria and a screening algorithm, including recommendations for complementary tests to be carried out in the different clinical scenarios.

The RA-ILD risk calculator provides a common strategy between rheumatologists and pulmonologists to improve the early diagnosis and quality of life of patients with RA-ILD and aid in clinical decision making.9

References

  • 1.
    Farquhar H, et al. Semin Respir Crit Care Med. 2019;40:194–207.
  • 2.
    Yunt ZX, Solomon JJ. Rheum Dis Clin North Am. 2015;41:225–36.
  • 3.
    Spagnolo P, et al. Arthritis Rheumatol. 2018;70:1544–54.
  • 4.
    Bongartz T, et al. Arthritis Rheum. 2010;62:1583–9.
  • 5.
    Shidara K, et al. Mod Rheumatol. 2010;20:280–6.
  • 6.
    Koduri G, et al. Rheumatology (Oxford). 2010;49:1483–9.
  • 7.
    Duarte AC, et al. Rheumatology (Oxford). 2019;58:2031–8.
  • 8.
    Hyldgaard C, Hilberg O, et al. Ann Rheum Dis. 2017;76:1700–6.
  • 9.
    Narvaez J, et al. Reumatol Clin. 2023;19:74-81